DuPont Merck/Cytogen Quadramet bone pain radiotherapeutic to be launched in mid-May.
Executive Summary
DUPONT MERCK/CYTOGEN QUADRAMET LAUNCH PLANNED FOR MID-MAY following FDA approval of the radiopharmaceutical for bone pain treatment March 28. The planned launch of samarium Sm 153 lexidronam depends on several factors, including regulatory approval from the Nuclear Regulatory Commission, DuPont Merck said. DuPont Merck estimates that the cost of a Quadramet procedure will be $2,000-$4,000 per treatment. Princeton, N.J.-based Cytogen acquired Quadramet from Dow and licensed U.S. manufacturing and marketing rights to DuPont Merck. Cytogen retains co-promotion rights in the U.S.